As of November 6, 2026, 4 holders' latest Schedule 13D or 13G filings report owning 5% or more of Processa Pharmaceuticals, Inc. The largest reported stake is HX Entertainment Ltd's, at 13%. 10 filings are on record since August 12, 2025 (Schedule 13D/A, February 23, 2026).
Sell to companies like Processa Pharmaceuticals, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Soleus Capital Master Fund, L.P. · Sole voting: 0 · Shared voting: 160,943 · Sole dispositive: 0 · Shared dispositive: 160,943 · SCHEDULE 13G, 2026-08-18
- · Holder: CVI Investments, Inc. · Percent: 7% · SCHEDULE 13G/A
- · Holder: HX Entertainment Ltd · Percent: 13% · SCHEDULE 13D/A
- · Holder: Mitchell P. Kopin · Percent: 8.1% · SCHEDULE 13G/A
- · Holder: CVI Investments, Inc. · Percent: 9% · SCHEDULE 13G/A
Processa Pharmaceuticals, Inc. has 10 Schedule 13D or 13G filings on record since 2025-08-12. 4 holders' latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| HX Entertainment Ltd | 13% | 305,644 | SCHEDULE 13D/A, 2026-02-23 | 2026-02-13 |
| 8.1% | 200,000 | SCHEDULE 13G/A, 2026-02-13 | 2025-12-31 | |
| CVI Investments, Inc. | 7% | 200,000 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| Soleus Capital Master Fund, L.P. | 5.8% | 160,943 | SCHEDULE 13G, 2026-08-18 | 2026-08-03 |
| Armistice Capital, LLC | 4.99% | 2,644,376 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
Holding shares or following this stake? See who's behind Processa Pharmaceuticals, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Processa Pharmaceuticals, Inc. and the records around it.
Processa Pharmaceuticals, Inc. elsewhere on the record
- Leadership changes Aug 2026
- Acquisition Jul 2026
- Who owns it
Companies that share a holder
- Soleus Capital Master Fund, L.P. also filed stake reports on 24 other companies: Beta Bionics, Inc. (Nov 2026), Evolus, Inc (Nov 2026), INSPIRE MEDICAL SYSTEMS, INC. (Nov 2026)
- CVI Investments, Inc. also filed stake reports on 48 other companies: Pine Tree Acquisition Corp. (Oct 2026), Sunshine Biopharma Inc. (Oct 2026), Outlook Therapeutics, Inc. (Aug 2026)
- Mitchell P. Kopin also filed stake reports on 55 other companies: SCWorx Corp. (Sep 2026), NFT Limited (Aug 2026), Silexion Therapeutics Corp (Aug 2026)
Watch Processa Pharmaceuticals, Inc.
Get an email when Processa Pharmaceuticals, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Processa Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Processa Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Processa Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Soleus Capital Master Fund, L.P. | 0 | 160,943 | 0 | 160,943 | SCHEDULE 13G, 2026-08-18 |
| Soleus Capital, LLC | 0 | 160,943 | 0 | 160,943 | SCHEDULE 13G, 2026-08-18 |
| Soleus Capital Group, LLC | 0 | 160,943 | 0 | 160,943 | SCHEDULE 13G, 2026-08-18 |
| Soleus Capital Management, L.P. | 0 | 160,943 | 0 | 160,943 | SCHEDULE 13G, 2026-08-18 |
| Soleus GP, LLC | 0 | 160,943 | 0 | 160,943 | SCHEDULE 13G, 2026-08-18 |
| Guy Levy | 0 | 160,943 | 0 | 160,943 | SCHEDULE 13G, 2026-08-18 |
The latest filing identifies Processa Pharmaceuticals, Inc. by CUSIP 74275C403 and gives its principal executive office as 601 21st Street, Suite 300, Vero Beach, FL 32960 (SCHEDULE 13G, 2026-08-18).
Purpose of Transaction (Item 4)
HX Entertainment Ltd
No material change from Amendment number one. The additional investment is consistent with The Chiliz Group's previously disclosed investment purpose and strategic interest in the Issuer.Item 4 of the SCHEDULE 13D/A filed 2026-02-23
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-12 | Mitchell P. Kopin | 9.99% | SCHEDULE 13G/A |
| 2025-08-13 | HX Entertainment Ltd | 10.9% | SCHEDULE 13D |
| 2025-08-14 | Armistice Capital, LLC | 4.99% | SCHEDULE 13G/A |
| 2025-08-14 | CVI Investments, Inc. | 9.9% | SCHEDULE 13G/A |
| 2025-10-15 | Chiliz Group Ltd. | 10.9% | SCHEDULE 13D/A |
| 2025-11-07 | CVI Investments, Inc. | 9% | SCHEDULE 13G/A |
| 2026-02-13 | Mitchell P. Kopin | 8.1% | SCHEDULE 13G/A |
| 2026-02-23 | HX Entertainment Ltd | 13% | SCHEDULE 13D/A |
| 2026-05-15 | CVI Investments, Inc. | 7% | SCHEDULE 13G/A |
| 2026-08-18 | Soleus Capital Master Fund, L.P. | 5.8% | SCHEDULE 13G |
Questions about who owns Processa Pharmaceuticals, Inc.
Who owns Processa Pharmaceuticals, Inc.?
On this page, 4 holders' latest ownership filings report 5% or more of Processa Pharmaceuticals, Inc.: HX Entertainment Ltd (13%, Schedule 13D/A, filed 2026-02-23), Mitchell P. Kopin (8.1%, Schedule 13G/A, filed 2026-02-13), CVI Investments, Inc. (7%, Schedule 13G/A, filed 2026-05-15) and Soleus Capital Master Fund, L.P. (5.8%, Schedule 13G, filed 2026-08-18).
Who are the largest shareholders of Processa Pharmaceuticals, Inc.?
By the share each holder's latest filing reports, the largest holders of Processa Pharmaceuticals, Inc. on this page are HX Entertainment Ltd (13%), Mitchell P. Kopin (8.1%) and CVI Investments, Inc. (7%).
When did HX Entertainment Ltd buy into Processa Pharmaceuticals, Inc.?
The filings give report dates, not purchase dates. The earliest filing from HX Entertainment Ltd on this page is the Schedule 13D, filed 2025-08-13, reporting 10.9%; its latest, Schedule 13D/A filed 2026-02-23, reports 13%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 10 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Processa Pharmaceuticals, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 4, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| July 29, 2026 | Leadership change: Sheila Gujrathi appointed, Director | — | Leadership changes | Source |
| July 28, 2026 | Acquired Vidya Therapeutics, Inc. | $200M | Acquisition | Source |
| April 30, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Processa Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.